74 - One Size Fits All? Antimicrobial Dosing in Obesity That Matters

Thursday, October 17, 2024

1:45 PM – 3:00 PM US PT

Location: 515 A

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Christopher Bland, PharmD, FCCP, FIDSA, BCPS

Albert W. Jowdy Professor in Pharmacy Care
Pharmacy
University of Georgia College of Pharmacy
Savannah, GA, United States
W. Justin Moore, PharmD, MS, BCPS, BCIDP (he/him/his)

Practice Coordinator, Antimicrobial & Diagnostic Stewardship; ID Clinical Pharmacist
Northwestern Medicine
Chicago, IL, United States

Faculty(s)

Jeffrey Barletta, PharmD, FCCM

Professor & Vice Chair
Pharmacy Practice
Midwestern University College of Pharmacy-Glendale Campus
Glendale, AZ, United States
Kayla Stover, Pharm.D. (she/her/hers)

Assistant Dean Jackson; Vice Chair and Professor
Pharmacy Practice
University of Mississippi School of Pharmacy
Jackson, MS, United States
Ronald Hall, II, PharmD, MSCS

Associate Professor
Pharmacy Practice
Jerry H. Hodge School of Pharmacy, Texas Tech University, Dallas Campus, Dallas, Texas
Dallas, TX, United States

Disclosure(s):

Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS: Merck and Co: Advisor/Consultant (Terminated, March 1, 2023), Honoraria (Terminated, March 1, 2023); Nestle/Seres: Honoraria (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

W. Justin Moore, PharmD, MS, BCPS, BCIDP: No financial relationships to disclose

Jeffrey Barletta, PharmD, FCCM: Wolters-Kluwer: Advisor/Consultant (Ongoing)

Kayla R. Stover, Pharm.D.: No financial relationships to disclose

Ronald G. Hall, PharmD, MSCS, II: Merck and Company, Inc.: Grant/Research Support (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify antibacterials, antivirals, and antifungals that require dose adjustment in obesity;
analyze data supporting adjustment of dosing within specific antibacterials, antivirals, and antifungals;
recommend appropriate dosing regimens in obese patients requiring antibacterials, antivirals, and antifungals.

Presentations:

1:45 PM – 2:10 PM US PT

Obesity Dosing in Antibacterials
Speaker: Jeffrey Barletta, PharmD, FCCM – Midwestern University College of Pharmacy-Glendale Campus
2:10 PM – 2:35 PM US PT

Is More Better? Dosing of Antivirals in Patients with Obesity
Speaker: Kayla R. Stover, Pharm.D. (she/her/hers) – University of Mississippi School of Pharmacy
2:35 PM – 3:00 PM US PT

Antifungal Dosing for Patients with Obesity
Speaker: Ronald G. Hall, II, PharmD, MSCS – Jerry H. Hodge School of Pharmacy, Texas Tech University, Dallas Campus, Dallas, Texas